N/A
N=41
An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies
Hematologic Malignancies
Bottom Line
View on ClinicalTrials.gov: NCT05433090 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Retention Rate — 38; 3 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Inpatient serious illness care program (Behavioral)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- University of Rochester
- Primary completion
- Aug 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Retention Rate |
38; 3 | — |
| SECONDARY Advance Directive Completion - HCP |
23; 18; 31; 10 | — |
| SECONDARY Advance Directive Completion - MOLST |
7; 34; 20; 21 | — |
Summary
This is a pilot study to assess the preliminary efficacy of an inpatient advance care planning intervention on outcomes in older patients with hematologic malignancies
Eligibility Criteria
Inclusion Criteria
- Age ≥60 years
- A diagnosis of hematologic malignancy [including but not limited to acute leukemia, myeloid malignancies (e.g., atypical CML, MDS/MPN overlap syndromes, CMML), multiple myeloma, lymphoma, or any other hematologic malignancies based on the primary oncologist's judgment]
- Able to provide informed consent
- Being managed in the inpatient setting
- English-speaking
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT05433090). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.